European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapy
Drug developers are racing to make gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just outside of Boston is poised to become ...
Harith Rajagopalan, Fractyl Health CEO May 11, 2026 07:00 AM EDT R&DCell/Gene Tx European regulators greenlight first clinical test of GLP-1 gene therapy Ryan Cross Senior Science Correspondent Drug developers are racing to make gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that